Phaseline

Companies › Kringle Pharma

Kringle Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Respiratory; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KP-100LI
Recombinant human hepatocyte growth factor (HGF)
HGFPhase 3Vocal Fold ScarFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05627648KP-100LIPhase 3Vocal Fold ScarRespiratoryFeb 2027

Targets

HGF (1)

Companies with the same targets

Claris Biotherapeutics AVEO Pharmaceuticals

Companies built like this

Bellus Health Inc. - a GSK company Biotest Areteia Therapeutics PureTech Renovion

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.